Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up – What’s Next?

by · The Cerbat Gem

Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $4.49, but opened at $4.82. Taysha Gene Therapies shares last traded at $4.9760, with a volume of 1,793,856 shares trading hands.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TSHA. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a research report on Friday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday. Citizens Jmp raised their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Wednesday, November 5th. Raymond James Financial began coverage on shares of Taysha Gene Therapies in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $13.00 target price for the company. Finally, Wall Street Zen cut shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $10.42.

Get Our Latest Stock Analysis on Taysha Gene Therapies

Taysha Gene Therapies Stock Performance

The stock’s fifty day simple moving average is $4.45 and its 200-day simple moving average is $3.34. The company has a market capitalization of $1.36 billion, a PE ratio of -15.02 and a beta of 1.06. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. On average, research analysts predict that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the completion of the transaction, the insider owned 1,006,439 shares in the company, valued at approximately $4,539,039.89. The trade was a 20.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 570,172 shares of company stock worth $2,341,906 in the last ninety days. Insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently bought and sold shares of TSHA. Vanguard Group Inc. raised its holdings in shares of Taysha Gene Therapies by 17.9% in the third quarter. Vanguard Group Inc. now owns 12,849,613 shares of the company’s stock worth $42,018,000 after acquiring an additional 1,955,486 shares during the last quarter. Octagon Capital Advisors LP raised its stake in Taysha Gene Therapies by 17.7% in the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock valued at $29,089,000 after purchasing an additional 1,892,500 shares during the last quarter. Jefferies Financial Group Inc. lifted its holdings in Taysha Gene Therapies by 4,105.3% in the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after purchasing an additional 10,068,479 shares in the last quarter. Vestal Point Capital LP boosted its stake in shares of Taysha Gene Therapies by 83.3% during the 3rd quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock worth $17,985,000 after purchasing an additional 2,500,000 shares during the last quarter. Finally, Polar Capital Holdings Plc grew its holdings in shares of Taysha Gene Therapies by 5.9% during the third quarter. Polar Capital Holdings Plc now owns 5,293,879 shares of the company’s stock worth $17,311,000 after buying an additional 293,879 shares in the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

(Get Free Report)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Read More